Market Size of Global HLA Typing Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
HLA Typing Market Analysis
The HLA typing market is expected to register a CAGR of 6.3% over the forecast period.
COVID-19 impacted the HLA typing market to a great extent due to the use of HLA typing in identifying the severity of COVID-19 diseases. For instance, according to a study published in 2021 by the European Journal of Medical Research, the HLA-A*11:01, HLA-B*51:01, and HLA-C*14:02 alleles were significantly associated with severe disease or worse outcomes. This led to increased adoption of HLA typing for COVID-19 patients to understand the severity of the disease, driving the market growth. However, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased down and disease screening services have been resumed.
The factors such as the growing burden of genetic diseases and the increasing number of organ transplants aid as a major contributors to the market growth. Furthermore, advancements in the products related to HLA typing are also expected to boost market growth.
According to the CDC data updated in May 2022, Sickle Cell Disease (SCD) affects approximately 100,000 Americans in 2021. Furthermore, according to news-medical.net updated in August 2022, thalassemia affects around 4.4 out of every 10,000 live births throughout the world every year. Such a high prevalence of genetic diseases across the globe will lead to increased adoption of HLA testing for the identification of genetic diseases, driving market growth.
Furthermore, rising initiatives from the key market players for the launch of innovative products into the market will further be expected to drive the growth of this market. For instance, in November 2021, NGeneBio a South Korean diagnostics firm received CE-IVD marking for its next-generation sequencing-based human leukocyte antigen (HLA) typing assay. This HLAaccuTest detects 11 HLA gene loci to verify the histocompatibility between bone marrow or organ donors and recipients before transplantation. This will lead to increased adoption of HLA typing tests during organ and bone marrow transplantation propelling the market growth.
In addition, rising awareness of HLA typing is also expected to bolster market growth. For instance, in August 2021, a free HLA typing test camp was conducted at Dr. Vinky Rughwani Thalassemia and Sickle Cell Center in collaboration with Sankalp India Foundation. Such campaigns will therefore lead to increased adoption of HLA typing for genetic testing, driving the market growth.
Thus, the rising prevalence of diseases and the developments in HLA typing are expected to drive market growth. However, small size of study population and ethical concern and stringent regulatory framework are expected to hinder the growth of the market.
